No Data
AI hotspots continue to boost! Most Medical stocks in Hong Kong strengthen, with Micro-invasion Siasun Robot&Automation rising over 20%.
How does Sister Wood perceive this hot topic of AI Medical? What positive impacts will the emergence of DeepSeek bring to the medical field?
2024 Annual Results Forecast Announcement
CHUNLI MEDICAL: ANNOUNCEMENT ON ESTIMATED RESULTS FOR THE YEAR 2024
CHUNLI MEDICAL (688236.SH): The net income for the year 2024 is expected to decrease by 53.99% to 61.19%.
On January 24, GELONGHU reported that CHUNLI MEDICAL (688236.SH) announced its performance forecast for the year 2024. According to preliminary calculations by the financial department, it is expected that the annual net income attributable to the parent company's owners will be between 107.824 million yuan and 127.824 million yuan, which represents a decrease of 150 million yuan to 170 million yuan compared to the same period last year, a year-on-year decrease of 53.99% to 61.19%. The net income attributable to the parent company's owners, excluding non-recurring gains and losses, is expected to be between 79.1283 million yuan and 99.1283 million yuan, compared to the same period last year.
CHUNLI MEDICAL (01858) has appointed Jie Fengbao as the secretary of the Board of Directors.
CHUNLI MEDICAL (01858) announced that the Board of Directors has recently received the submission from the company's Board of Directors Secretary, Ms. Zhang Lili...
chunli medical (688236.SH): accumulated repurchased 0.226% of shares
On December 2, Gelonghui reported that Chunli Medical (688236.SH) announced that as of November 30, 2024, the company has cumulatively repurchased 868,145 shares through the Shanghai Stock Exchange trading system via centralized bidding, accounting for 0.226% of the company's total share capital. The highest price for the repurchase was 15.96 yuan/share, the lowest price was 12.09 yuan/share, and the total amount paid was 12,018,864.19 yuan (excluding transaction fees).
